Management of narcolepsy: Defining the role of modafinil

Disease Management and Health Outcomes

Volumn 8, Issue 2, 2000, Pages 99-111

  Comer, Alison M ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMPHETAMINE DERIVATIVE; CLOMIPRAMINE; CLONAZEPAM; FEMOXETINE; FLUOXETINE; IMIPRAMINE; MAZINDOL; METHYLPHENIDATE; MODAFINIL; PEMOLINE; PROTRIPTYLINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VILOXAZINE;

ALERTNESS; ANXIETY; BEHAVIOR MODIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG TOLERANCE; HEADACHE; HUMAN; NARCOLEPSY; NAUSEA; NERVOUSNESS; REVIEW; SOMNOLENCE;

EID: 0033875550     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200008020-00005     Document Type: Review

References (82)

1. 1. McClellan KJ, Spencer CM. Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy. CNS Drugs 1998 Apr; 9: 311-24
2. 2. Bergstrom DL, Keller C. Narcolepsy: pathogenesis and nursing care. J Neurosci Nurs 1992 Jun; 24: 153-7
3. 3. Broughton WA, Broughton RJ. Psychosocial impact of narcolepsy. Sleep 1994 (17): S45-9
4. 4. Aldrich MS. Narcolepsy. Neurology 1992 Jul; 42 Suppl. 6: 34-43
5. 5. Douglas NJ. The psychosocial aspects of narcolepsy. Neurology 1998 Feb; 50 Suppl. 1: S27-30
6. 6. Roth T, Roehrs TA. Etiologies and sequelae of excessive daytime sleepiness. Clin Ther 1996 Jul-Aug; 18: 562-76
7. 7. Diagnostic Classification Steering Committee. Thorpy MJ (chairman). The International Classification of Sleep Disorders: diagnostic and coding manual. Rochester (MN): American Sleep Disorders Association, 1990
8. 8. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998 Feb; 50 Suppl. 1: S16-22
9. 9. Pelin Z, Guilleminault C, Risch N, et al. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 1998 Jan; 51: 96-100
10. 10. Mignot E, Hayduk R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997 Nov; 20: 1012-20
11. 11. Kramer RE, Dinner DS, Braun WE, et al. HLA-DR2 and narcolepsy. Arch Neurol 1987 Aug; 44: 853-5
12. 12. Singh SM, George CFP, Kryger MH, et al. Genetic heterogeneity in narcolepsy [letter]. Lancet 1990 Mar 24; 335: 726-7
13. 13. Rogers AE, Meehan J, Guilleminault C, et al. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997 Jun; 48: 1550-6
14. 14. Wing Y-K, Chen C-N, Ho CKW HLA DR2 and DQ1 frequency among narcoleptic patients in Hong Kong Chinese. Psychiatr Clin Neurosci 1998 Oct; 52: 523-7
15. 15. Hayduk R, Flodman P, Spence MA, et al. HLA haplotypes, polysomnography, and pedigrees in a case series of patients with narcolepsy. Sleep 1997; 20 (10): 850-7
16. 16. Wilner A, Steinman L, Lavie P, et al. Narcolepsy-cataplexy in Israeli Jews is associated exclusively with the HLA DR2 haplotype. A study at the serological and genomic level. Hum Immunol 1988; 21 (1): 15-22
17. 17. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999 Aug 6; 98: 365-76
18. 18. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999 Aug 20; 98: 437-51
19. 19. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000 Jan 1; 355: 39-40
20. 20. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998 Jan; 95: 322-7
21. 21. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998 Dec 1; 12 (23): 9996-10015
22. 22. Aldrich MS, Naylor MW. Narcolepsy associated with lesions of the diencephalon. Neurology 1989 Nov; 39: 1505-8
23. 23. Bassetti C, Aldrich MS. Narcolepsy. Neurol Clin 1996 Aug; 14: 545-71
24. 24. Hublin C, Partinen M, Kaprio J, et al. Epidemiology of narcolepsy. Sleep 1994 Dec; 17 (8) Suppl.: S7-12
25. 25. Wing Y-K, Chiu HF, Ho CK, et al. Narcolepsy in Hong Kong Chinese - a preliminary experience. Aust N Z J Med 1994 Jun; 24: 304-6
26. 26. Stores G. Recognition and management of narcolepsy. Arch Dis Child 1999; 81 (6): 519-24
27. 27. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999 Sep 15; 22: 757-65
28. 28. Hublin C. Narcolepsy: current drug treatment options. CNS Drugs 1996; 5 (6): 426-36
29. 29. Practice parameters for the use of stimulants in the treatment of narcolepsy. Standards of Practice Committee of the American Sleep Disorders Association [published erratum appears in Sleep 1994 Dec; 17 (8): 748]. Sleep 1994 Jun; 17: 348-51
30. 30. Richardson JW, Fredrickson PA, Lin SC. Narcolepsy update. Mayo Clin Proc 1990 Jul; 65: 991-8
31. 31. Minimising the consequences of narcolepsy. Drug Ther Perspect 1996 Nov 25; 8 11: 7-10
32. 32. Nishino S, Mignot E. Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations. Clin Pharmacokinet 1999 Oct; 37: 305-30
33. 33. Kam PCA, Yoong FFY. Gamma-hydroxybutyric acid: an emerging recreational drug. Anaesthesia 1998; 53: 1195-8
34. 34. Mitler MM, Aldrich MS, Koob GF, et al. Narcolepsy and its treatment with stimulants. ASDA Standards of Practice. Sleep 1994 Jun; 17: 352-71
35. 35. Fry JM. Treatment modalities for narcolepsy. Neurology 1998 Feb; 50 Suppl. 1: S43-8
36. 36. Birmaher B, Greenhill LL, Cooper TB, et al. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 1989 Sep; 28 (5): 768-72
37. 37. Novartis Pharmaceuticals Corporation. Ritalin® and Ritalin-SR® (methylphenidate hydrochloride USP) prescribing information. East Hanover (NJ): Novartis, 1999
38. 38. Marotta PJ, Roberts EA. Pemoline hepatotoxicity in children. J Pediatr 1998 May; 132 (5): 894-7
39. 39. Cylert (pemoline) June 1999 labeling [online]. Available from: URL: http://www.fda.gov/medwatch/safety/1999/cylert19.htm [Accessed 2000 May 1]
40. 40. Alvarez B, Dahlitz M, Grimshaw J, et al. Mazindol in long-term treatment of narcolepsy. Lancet 1991 May 25; 337: 1293-4
41. 41. Shindler J, Schachter M, Brincat S, et al. Amphetamine, mazindol, and fencamfamin in narcolepsy. BMJ 1985 Apr 20; 290: 1167-70
42. 42. Parkes JD, Schachter M. Mazindol in the treatment of narcolepsy. Acta Neurol Scand 1979; 60: 250-4
43. 43. Iijima S, Sugita Y, Teshima Y, et al. Therapeutic effects of mazindol on narcolepsy. Sleep 1986; 9 (1): 265-8
44. 44. Hublin C, Partinen M, Heinonen EH, et al. Selegiline in the treatment of narcolepsy. Neurology 1994; 44: 2095-101
45. 45. Mayer G, Ewert Meier K, Klinik Hephata. Selegiline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 1995; 18 (4): 306-19
46. 46. Parkes JD. Sleep and its disorders. London: WB. Saunders Company, 1985
47. 47. Parkes JD, Baraitser M, Marsden CD, et al. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand 1975; 52: 337-53
48. 48. Guilleminault C, Pelayo R. Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs 2000 Jan-Feb; 2: 1-9
49. 49. Ferraro L, Antonelli T, O'Connor WT, et al. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997 Dec; 42: 1181-3
50. 50. Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992 Sep 25; 591: 319-26
51. 3 receptor. Neurosci Lett 1996 Dec 6; 220: 5-8
52. 52. Cephalon. Provigil® (modafinil) prescribing information. West Chester (PA): Cephalon, 1999
53. 53. Modiodal (modafinil) prescribing information [online] [in French]. Fiche D'Information Therapeutique: Medicaments D'Exception; 1999 Nov 7. Available from: URL: http://agmed.sante.gouv.fr/fr/htm/5/modiodal.htm [Accessed 2000 Jun 1]
54. 54. Merckle GmbH. Vigil® (modafinil) prescribing information [in German]. Blaubeuren, Germany: Merckle, 1999 Aug
55. 55. Mehta DK, Martin J, Blackley HKL, et al., editors. British National Formulary. 39th ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2000
56. 56. Besset A, Chetrit M, Carlander B, et al. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiol Clin 1996; 26: 60-6
57. 57. Laffont F, Mayer G, Minz M. Modafinil in diurnal sleepiness. A study of 123 patients. Sleep 1994 Dec; 17 (8) Suppl.: S113-5
58. 58. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsych Biol Psychiatry 1988; 12: 695-700
59. 59. Declerck AC. Long-term effects of modafinil (MOD) [abstract]. Eur J Neurol 1999 Sep; 6 Suppl. 3: 43
60. 60. Declerck AC, Lammers GJ, de Weerd AW, et al. Modafinil is an effective alternative to methylphenidate in narcolepsy treatment: a multicenter open-label study in The Netherlands [abstract no. SL12]. Eur J Neurol 1998 Sep; 5 Suppl. 3: S210-211
61. 61. Mitler MM, Harsh J, Hirshkowitz M, et al. Long-term efficacy and safety of modafinil (Provigil®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 2000 Jul; 1: 231-43
62. 62. Besset A, Tafti M, Villemin E, et al. Effects of modafinil (300 mg) on sleep, sleepiness and alertness of narcoleptic patients [in French]. Neurophysiol Clin 1993 Jan; 23: 47-60
63. 63. Broughton RJ, Fleming JAE, George CFP, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997 Aug; 49: 444-51
64. 64. Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep 1994 Dec; 17 Suppl.: S107-12
65. 65. Boivin DB, Montplaisir J, Petit D, et al. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993 Feb; 16: 46-53
66. 66. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43: 88-97
67. 67. Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000 Apr 1; 1 (2): 109-16
68. 68. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000; 54: 1166-75
69. 69. Schwartz JR, Feldman NT, Fry JM. Effect of Provigil® (modafinil) on excessive daytime sleepiness associated with narcolepsy in patients who previously received unsatisfactory treatment with dextroamphetamine, methylphenidate or pemoline [abstract no. 1189.K2]. Sleep 2000; 23 Suppl. 2: A306
70. 70. Bensimon G, Benoit D, Lacomblez L, et al. Antagonism by modafinil of the psychomotor and cognitive impairment induced by sleep-deprivation in 12 healthy volunteers. Eur Psychiatry 1991; 6 (2): 93-7
71. 71. Baranski JV, Pigeau RA. Self-monitoring cognitive performance during sleep deprivation: effects of modafinil, d-amphetamine and placebo. J Sleep Res 1997; 6: 84-91
72. 72. Goswami M. The influence of clinical symptoms on quality of life in patients with narcolepsy. Neurology 1998 Feb; 50 Suppl. 1: S31-6
73. 73. Feldman NT, Schwartz JR, Harsh J. Effect of Provigil® (modafinil) on the quality of life and mood of patients who previously received unsatisfactory treatment with dexamphetamine, methylphenidate, or pemoline for excessive daytime sleepiness associated with narcolepsy [abstract no. 1190.K2]. Sleep 2000; 23 Abstract Suppl. 2: A307
74. 74. Moachon G, Kanmacher I, Clenet M, et al. Pharmacokinetic profile of modafinil. Drugs Today 1996 Jun; 32: 327-37
75. 75. Cephalon. Provigil off-label use potential raised during NDA review. Pharm Approvals Monthly 1999 Sep: 31-5
76. 76. Warot D, Corruble E, Payan C, et al. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo. Eur Psychiatry 1993; 8 (4): 201-8
77. 77. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000; 14 (1): 53-60
78. 78. Grözinger M, Härtter S, Hiemke C, et al. Interaction of modafinil and clomipramine as comedication in a narcoleptic patient. Clin Neuropharmacol 1998 Mar-Apr; 21: 127-9
79. 79. Terzoudi M, Gavrieldou P, Heilakos G, et al. Fatigue in multiple sclerosis: evaluation and a new pharmacological approach [abstract no. P01.100]. Neurology 2000 Apr; 54 Suppl. 3: A61-62
80. 80. Rammohan KW, Rosenberg JH, Pollak CP, et al. Modafinil -efficacy and safety for the treatment of fatigue in patients with multiple sclerosis [abstract no. S11.004]. Neurology 2000 Apr; 54 Suppl. 3: A24
81. 81. Arnulf I, Homeyer P, Garma L, et al. Modafinil in obstructive sleep apnea-hypopnea syndrome: a pilot study in 6 patients. Respiration 1997; 64: 159-61
82. 82. Provigil in ADHD trials. Scrip Mag 1999 Oct 8; 2479: 27